Merck Announces That IMPROVE-IT Achieved Primary Endpoint; Data To Be Presented At American Heart Association Scientific Sessions Today

Merck

, known as MSD outside the United States and Canada, today said that IMPROVE-IT met its primary endpoint. The results are scheduled to be presented at the American Heart Association Scientific Sessions later today. The data are embargoed by the American Heart Association until the start of the late-breaking clinical trials session at 10:45 a.m. CT today.